[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334948-105":59,"doc-detail-334948-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","nectin4-amplification-is-frequent-in-solid-tumors-and-predicts-enfortumab-vedotin-response-in-metastatic-urothelial-cancer","NECTIN4 Ampliﬁcation Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer","","Enfortumab vedotin (EV) is approved for metastatic urothelial cancer (mUC), yet durable benefit occurs only in a limited, poorly defined subgroup. This study evaluates NECTIN4 amplification as a genomic biomarker for predicting EV response. A NECTIN4-specific FISH assay measured NECTIN4 copy-number variations in an EV-treated cohort and non-EV-treated metastatic biopsies, supported by TCGA pan-cancer analyses.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nectin4-amplification-is-frequent-in-solid-tumors-and-predicts-enfortumab-vedotin-response-in-metastatic-urothelial-cancer/334948/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nectin4-amplification-is-frequent-in-solid-tumors-and-predicts-enfortumab-vedotin-response-in-metastatic-urothelial-cancer/334948.png","ImageObject",300,407,{"name":92,"@type":93},"Maeve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of this study?","Question",{"text":112,"@type":113},"The study aims to determine whether NECTIN4 amplification can serve as a genomic biomarker to predict enfortumab vedotin response in metastatic urothelial cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was NECTIN4 amplification assessed?",{"text":117,"@type":113},"Researchers developed a NECTIN4-specific fluorescence in situ hybridization (FISH) assay to evaluate NECTIN4 copy number variations in multicenter patient cohorts and correlated results with protein expression, treatment responses, and outcomes.",{"name":119,"@type":110,"acceptedAnswer":120},"What do the results show about NECTIN4 amplification and EV response?",{"text":121,"@type":113},"In the EV-treated cohort, NECTIN4 amplifications were associated with higher objective response rates to EV and a substantially reduced risk of death in multivariable analysis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334948,1790512645,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":4},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","Original Reports | Genitourinary Cancer  \nNECTIN4 Ampliﬁcation Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer  \nNiklas Klmper, MD1,2,3,4 ; Ngoc Khanh Tran1,2,3 ; Stefanie Zschbitz, MD5; Oliver Hahn, MD6 ; Thomas Bttner, MD1,3 ;  \nFlorian Roghmann, MD4,7; Christian Bolenz, MD4,8; Friedemann Zengerling, MD4,8; Constantin Schwab, MD9 ; Dora Nagy, MD3,10;  \nMarieta Toma, MD3,10 ; Glen Kristiansen, MD3,4,10; Hendrik Heers, MD11 ; Philipp Ivanyi, MD12 ; Gnter Niegisch, MD13 ;  \nCamilla Marisa Grunewald, MD13 ; Christopher Darr, MD14 ; Arian Farid, MD15; Katrin Schlack, MD16 ; Mahmoud Abbas, MD17;  \nCan Aydogdu, MD18 ; Jozeﬁna Casuscelli, MD18; Theresa Mokry, MD19 ; Michael Mayr, MD20; Dora Niedersß-Beke, MD21;  \nSteffen Rausch, MD22  ; Dimo Dietrich, PhD23  ; Jonas Saal, MD2,3,24  ;Jrg Ellinger, MD1,3  ; Manuel Ritter, MD1,3,4  ; Abdullah Alajati, PhD1,3; Christoph Kuppe, MD, PhD25 ; Joshua Meeks, MD, PhD26 ; Francisco E. Vera Badillo, MD27 ; J. Alberto Nakauma-Gonzlez, PhD28 ; Joost Boormans, MD28; Kerstin Junker, MD29 ; Arndt Hartmann, MD4,30,31,32; Viktor Grnwald, MD33 ; Michael Hlzel, MD, PhD2,3 ; and Markus Eckstein, MD4,30,31,32   \nDOI [https://doi.org/10.1200/JCO.23.01983](https://doi.org/10.1200/JCO.23.01983)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | The anti-NECTIN4 antibody-drug conjugate enfortumabvedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable beneﬁt is only achieved in a small, yet uncharacterized patient subset. NECTIN4 is located on chromosome 1q23.3, and 1q23.3 gains represent frequent copy number variations (CNVs) in urothelial cancer. Here, we aimed to evaluate NECTIN4 ampliﬁcations asa genomic biomarker to predict EV response in patients with mUC. |\n| MATERIALS\u003Cbr>AND METHODS | We established a NECTIN4-speciﬁc ﬂuorescence in situ hybridization (FISH) assay to assess the predictive value of NECTIN4 CNVs in a multicenter EV-treated mUC patient cohort (mUC-EV, n 5 108) . CNVs were correlated with membranous NECTIN4 protein expression, EV treatment responses, and outcomes. We also assessed the prognostic value of NECTIN4 CNVs measured in metastatic biopsies of non–EV-treated mUC (mUC-non-EV, n 5 103) . Furthermore, we queried The Cancer Genome Atlas (TCGA) data sets (10,712 patients across 32 cancer types) for NECTIN4 CNVs. |\n| RESULTS | NECTIN4 ampliﬁcations are frequent genomic events in muscle-invasive bladder cancer (TCGA bladder cancer data set: approximately 17%) and mUC (approximately 26% in our mUC cohorts) . In mUC-EV, NECTIN4 ampliﬁcation represents a stable genomic alteration during metastatic progression and associates with enhanced membranous NECTIN4 protein expression. Ninety-six percent (27 of 28) of patients with NECTIN4 ampliﬁcations demonstrated objective responses to EV compared with 32%(24 of 74) in the nonampliﬁed subgroup (P \u003C .001) . In multivariable Cox analysis adjusted for age, sex, and Bellmunt risk factors, NECTIN4 ampliﬁcations led to a 92% risk reduction for death (hazard ratio, 0 . 08 [95% CI, 0 . 02 to 0 .34]; P \u003C . 001) . In the mUC-non-EV, NECTIN4 ampliﬁcations were not associated with outcomes. TCGA Pan-Cancer analysis demonstrated that NECTIN4 ampliﬁcations occur frequently in other cancers, for example, in 5%-10% of breast and lung cancers. |\n| CONCLUSION | NECTIN4 ampliﬁcations are genomic predictors of EV responses and long-term survival in patients with mUC. |\n\nACCOMPANYING CONTENT  \n Appendix  \nAccepted February 26, 2024 Published April 24, 2024  \nJ Clin Oncol 42:2446-2455 © 2024 by American Society of Clinical Oncology  \nView Online Article  \nLicensed under the Creative  \nCommons Attribution 4.0 License  \nINTRODUCTION  \nThe anti-NECTIN4 antibody-drug conjugate (ADC) enfortumabvedotin (EV) has been approved for previously treated patients with metastatic urothelial cancer (mUC).1,2 The combination of  \nEV plus pembrolizumab (EV/P) was recently approved in metastatic, treatme","cbCaikuCipHpi6wk","https://ap.wps.com/l/cbCaikuCipHpi6wk","pdf",9371760,16,"English","# Abstract\n## Purpose\n## Materials and Methods\n## Results\n## Conclusion\n# Introduction\n# Context","[{\"question\":\"What is the main goal of this study?\",\"answer\":\"The study aims to determine whether NECTIN4 amplification can serve as a genomic biomarker to predict enfortumab vedotin response in metastatic urothelial cancer.\"},{\"question\":\"How was NECTIN4 amplification assessed?\",\"answer\":\"Researchers developed a NECTIN4-specific fluorescence in situ hybridization (FISH) assay to evaluate NECTIN4 copy number variations in multicenter patient cohorts and correlated results with protein expression, treatment responses, and outcomes.\"},{\"question\":\"What do the results show about NECTIN4 amplification and EV response?\",\"answer\":\"In the EV-treated cohort, NECTIN4 amplifications were associated with higher objective response rates to EV and a substantially reduced risk of death in multivariable analysis.\"}]","NECTIN4 Ampliﬁcation Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer | PDF",1790008954]